- Home
- DAWN vs LADR Comparison
DAWN vs LADR Comparison
Compare DAWN & LADR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- LADR
- Stock Information
- Founded
- DAWN 2018
- LADR 2008
- Country
- DAWN United States
- LADR United States
- Employees
- DAWN N/A
- LADR N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- LADR Real Estate Investment Trusts
- Sector
- DAWN Health Care
- LADR Real Estate
- Exchange
- DAWN Nasdaq
- LADR Nasdaq
- Market Cap
- DAWN 1.3B
- LADR 1.5B
- IPO Year
- DAWN 2021
- LADR 2014
- Fundamental
- Price
- DAWN $12.79
- LADR $11.43
- Analyst Decision
- DAWN Strong Buy
- LADR Buy
- Analyst Count
- DAWN 7
- LADR 6
- Target Price
- DAWN $36.17
- LADR $13.33
- AVG Volume (30 Days)
- DAWN 1.0M
- LADR 690.6K
- Earning Date
- DAWN 10-30-2024
- LADR 02-06-2025
- Dividend Yield
- DAWN N/A
- LADR 8.06%
- EPS Growth
- DAWN N/A
- LADR N/A
- EPS
- DAWN N/A
- LADR 0.76
- Revenue
- DAWN $101,953,000.00
- LADR $257,005,000.00
- Revenue This Year
- DAWN N/A
- LADR N/A
- Revenue Next Year
- DAWN $36.10
- LADR N/A
- P/E Ratio
- DAWN N/A
- LADR $15.01
- Revenue Growth
- DAWN N/A
- LADR N/A
- 52 Week Low
- DAWN $11.94
- LADR $10.10
- 52 Week High
- DAWN $18.07
- LADR $12.48
- Technical
- Relative Strength Index (RSI)
- DAWN 39.97
- LADR 37.15
- Support Level
- DAWN $12.26
- LADR $11.74
- Resistance Level
- DAWN $12.81
- LADR $11.97
- Average True Range (ATR)
- DAWN 0.52
- LADR 0.23
- MACD
- DAWN -0.05
- LADR -0.08
- Stochastic Oscillator
- DAWN 28.94
- LADR 26.55
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
About LADR Ladder Capital Corp
Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.